Company intelligence / Profile preview
ExCellThera
Montreal, Quebec, Canadaexcellthera.com ↗
- Ownership
- Private
- Employees
- ~22
- Development stage
- Other
01
Overview
ExCellThera has developed a proprietary technology to expand and rejuvenate blood stem and immune cells using its ECT‑001 platform. The company’s lead asset leverages the small molecule UM171 to improve outcomes for patients requiring hematopoietic cell transplantation. Early clinical data suggest improved engraftment and potential benefits over standard approaches, but detailed trial results are not provided in the available sources.
- Therapeutic areas
- OtherHematology
- Modalities
- Small molecules (e.g., UM171)Cell therapy (expanded blood stem and immune cells)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on ExCellThera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExCellThera.